Evidence map›Paper›PMID 41551884›Full record

ArticleMaterials today. Bio2026

A sustainable ROS cycle generator (SRCG) for tumor chemodynamic therapy.

Yuling Zhang, Silue Zeng, Chuanyu Tang, Shuangqin He, Yingying Pan, Shuchang Li, Yaguang Ren, Mifang Li, Jianwei Tan, Min Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuling ZhangLab of Molecular Imaging and Medical Intelligence, Department of Radiology, Longgang Central Hospital of Shenzhen (Shenzhen Clinical Medical College, Guangzhou University of Chinese Medicine), Shenzhen, 518116, China.
Silue ZengResearch Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Chuanyu TangDepartment of Hepatobiliary Surgery I, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
Shuangqin HeLab of Molecular Imaging and Medical Intelligence, Department of Radiology, Longgang Central Hospital of Shenzhen (Shenzhen Clinical Medical College, Guangzhou University of Chinese Medicine), Shenzhen, 518116, China.
Yingying PanResearch Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Shuchang LiResearch Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Yaguang RenResearch Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Mifang LiLab of Molecular Imaging and Medical Intelligence, Department of Radiology, Longgang Central Hospital of Shenzhen (Shenzhen Clinical Medical College, Guangzhou University of Chinese Medicine), Shenzhen, 518116, China.
Jianwei TanResearch Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Min ZhangResearch Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Jingqin ChenResearch Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Chengbo LiuResearch Center for Biomedical Optics and Molecular Imaging, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Lingyan ZhangLab of Molecular Imaging and Medical Intelligence, Department of Radiology, Longgang Central Hospital of Shenzhen (Shenzhen Clinical Medical College, Guangzhou University of Chinese Medicine), Shenzhen, 518116, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemodynamic therapy (CDT) provides an alternative strategy for tumor therapy. However, the insufficient generation of intratumoral reactive oxygen species (ROS) has been a key challenge encountered in the application and translation of CDT. Herein, we develop a sustainable ROS cycle generator (SRCG) capable of continuously producing ROS for high-efficiency tumor CDT. SRCG uses a porous metal‒organic framework material (Cu-ZIF8) as a carrier for concurrent delivery of glucose oxidase (GOX) and hyaluronidase (HAase). This approach results in a highly efficient nanoreactor, Cu-ZIF8@GOX@HAase (CZGH), capable of releasing GOX and HAase under acidic conditions to hydrolyze glucose and hyaluronic acid. The resulting products can react with the Cu ions in CZ to produce high concentrations of ROS, promoting tumor cell death. Furthermore, CZGH can degrade the extracellular matrix (ECM) and enhance tumor permeability, which facilitates its delivery and relieves hypoxia. This allows for the infiltration of glucose into the tumor, ensuring a sufficient glucose supply from the bloodstream to the SRCG system, and hence resulting in a sustainable ROS production. The effectiveness of SRCG in CDT has been demonstrated both

Identifiers

PMID41551884
PMCPMC12810555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.